When looking at the institutional investors followed by Insider Monkey, Kevin Kotlers Broadfin Capital has the number one position in RedHill Biopharma Ltd ADR (NASDAQ:RDHL), worth close to $10.7 million, comprising 0.6% of its total 13F portfolio. The second most bullish fund manager is Samuel Isaly of OrbiMed Advisors, with a $7.3 million position; 0.1% of its 13F portfolio is allocated to the company. Remaining peers with similar optimism consist of Jacob Gottliebs Visium Asset Management, Hal Mintzs Sabby Capital and Israel Englanders Millennium Management.
As industrywide interest jumped, specific money managers have jumped into RedHill Biopharma Ltd ADR (NASDAQ:RDHL) headfirst. Visium Asset Managemen assembled the biggest position in RedHill Biopharma Ltd ADR (NASDAQ:RDHL). Visium Asset Management had $6.5 million invested in the company at the end of the quarter. Sabby Capital also made a $2.2 million investment in the stock during the quarter. The only other fund with a brand new RDHL position is Millennium Management.
www.insidermonkey.com/blog/...l-biopharma-ltd-adr-rdhl-388050/